Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Top Cited Papers
- 1 June 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 38 (6), 756-767
- https://doi.org/10.1097/pas.0000000000000208
Abstract
On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathologic classification of neuroendocrine (NE) differentiation in prostate cancer. New clinical and molecular data emerging from prostate cancers treated by contemporary androgen deprivation therapies, as well as primary lesions, have highlighted the need for refinement of diagnostic terminology to encompass the full spectrum of NE differentiation. The classification system consists of: Usual prostate adenocarcinoma with NE differentiation; 2) Adenocarcinoma with Paneth cell NE differentiation; 3) Carcinoid tumor; 4) Small cell carcinoma; 5) Large cell NE carcinoma; and 5) Mixed NE carcinoma - acinar adenocarcinoma. The article also highlights “prostate carcinoma with overlapping features of small cell carcinoma and acinar adenocarcinoma” and “castrate-resistant prostate cancer with small cell cancer-like clinical presentation”. It is envisioned that specific criteria associated with the refined diagnostic terminology will lead to clinically relevant pathologic diagnoses that will stimulate further clinical and molecular investigation and identification of appropriate targeted therapies.Keywords
This publication has 83 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancerVirchows Archiv, 2012
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsCancer Discovery, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- ERG–TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal originLaboratory Investigation, 2011
- ERG gene rearrangements are common in prostatic small cell carcinomasLaboratory Investigation, 2011
- Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progressionLaboratory Investigation, 2009
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment ModalitiesEuropean Urology, 2005
- Carcinoid Tumour of the Prostate Associated with Inappropriate ACTH SecretionBritish Journal of Urology, 1985